An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10

LM DeAngelis;W Seiferheld;SC Schold;B Fisher;CJ Schultz Journal of Clinical Oncology 20(24):4643-4648

Secondary analyis of RTOG 9310: an Intergroup phase II combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy

BJ Fisher;W Sieferheld;C Schultz;L De Angelis;D Nelson;SC Schold;W Curran Int J Radiat Oncol Biol Phys 51(3):166(#297)

Secondary analysis of RTOG 9310: an Intergroup phase II combined modality treatmetn of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy

BJ Fisher;W Seiferheld;C Schultz;L DeAngelis;D Nelson;SC Schold;W Curran Neuro-Oncology 3(4):348-349 (#325)

Radiation therapy (RT) alone vs. pre-RT chemotherapy (CTX) for the treatment of primary CNS lymphoma (PCNSL): age matched survival analysis of RTOG-83-15 and RTOG 93-10.

C Schultz;C Scott;L DeAngelis;D Nelson;C Schold;W Curran Proc of the American Society of Clinical Oncology 19:159a(#617)

Combined Modality treatment of primary central nervous system lymphoma (PCNSL) RTOG 93-10.

L DeAngelis;W Seiferheld;S Schold;B Fisher;R Byhardt Proc of the American Society of Clinical Oncology 18:140a(#537)